Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Jan 7;332(7532):22-7.
doi: 10.1136/bmj.38666.653600.55. Epub 2005 Dec 8.

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Christian M Jespersen  1 , Bodil Als-Nielsen, Morten Damgaard, Jørgen Fischer Hansen, Stig Hansen, Olav H Helø, Per Hildebrandt, Jørgen Hilden, Gorm B Jensen, Jens Kastrup, Hans Jørn Kolmos, Erik Kjøller, Inga Lind, Henrik Nielsen, Lars Petersen, Christian Gluud; CLARICOR Trial Group
Affiliations
Randomized Controlled Trial

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Christian M Jespersen et al. BMJ. .

Erratum in

  • BMJ. 2006 Jan 21;332(7534):151

Abstract

Objective: To determine if the macrolide clarithromycin affects mortality and cardiovascular morbidity in patients with stable coronary heart disease.

Design: Centrally randomised multicentre trial. All parties at all stages were blinded. Analyses were by intention to treat.

Setting: Five Copenhagen University cardiology departments and a coordinating centre.

Participants: 13,702 patients aged 18 to 85 years who had a discharge diagnosis of myocardial infarction or angina pectoris in 1993-9 and alive in August 1999 were invited by letter; 4373 were randomised.

Interventions: Two weeks' treatment with clarithromycin 500 mg/day or matching placebo.

Primary outcome: composite of all cause mortality, myocardial infarction, or unstable angina pectoris during three years' follow-up. Secondary outcome: composite of cardiovascular mortality, myocardial infarction, or unstable angina pectoris. The outcomes were obtained from Danish registers and were blindly assessed by the event committee.

Results: 2172 participants were randomised to clarithromycin and 2201 to placebo. We found no significant effects of clarithromycin on the primary outcome (hazard ratio 1.15, 95% confidence interval 0.99 to 1.34) or secondary outcome (1.17, 0.98 to 1.40). Mortality was significantly higher in the clarithromycin arm (1.27, 1.03 to 1.54; P = 0.03) as a result of significantly higher cardiovascular mortality (1.45, 1.09 to 1.92; P = 0.01).

Conclusions: Short term clarithromycin in patients with stable coronary heart disease may cause significantly higher cardiovascular mortality. The long term safety of clarithromycin in patients with stable ischaemic heart disease should be examined. Trial registration ClinicalTrials.gov NCT00121550.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Flow of participants through enrolment, randomisation, and follow-up of CLARICOR trial
Fig 2
Fig 2
Kaplan-Meier estimate (with 95% confidence intervals) of the primary outcome measure (composite of all cause mortality, myocardial infarction, or unstable angina pectoris) according to intervention. Figures below the diagram are biannual numbers at risk in the clarithromycin and placebo groups
Fig 3
Fig 3
Kaplan-Meier estimate (with 95% confidence intervals) of cardiovascular mortality according to intervention. Figures below the diagram are biannual number at risk in the clarithromycin and placebo groups
See this image and copyright information in PMC

Republished in

Comment in

References

    1. Libby P, Ridker PM, Maser A. Inflammation and atherosclerosis. Circulation 2002;105: 1135-43. - PubMed
    1. Muhlestein JB, Anderson JL. Infectious serology and atherosclerosis: how burdensome is the risk? Circulation 2003;107: 220-2. - PubMed
    1. Gelfand EV, Cannon CP. Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J 2004;147: 202-9. - PubMed
    1. Gieffers J, Solbach W, Maass M. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. Cardiovasc Drugs Ther 2001;15: 259-62. - PubMed
    1. Melissano G, Blasi F, Esposito G, Tarsia P, Dordoni L, Arosio C, et al. Chlamydia pneumoniae eradication from carotid plaques: results of an open, randomised treatment study. Eur J Vasc Endovasc Surg 1999;18: 355-9. - PubMed

Publication types

Associated data